Dogwood Therapeutics Inc (DWTX)

$5.88 +0.26 (4.63%)
Market Cap 13.48M
Revenue (ttm) 0.00
Net Income (ttm) -12.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 133,600
Avg Vol 932,402
Day's Range N/A - N/A
Shares Out 2.29M
Stochastic %K 45%
Beta 1.89
Analysts Strong Sell
Price Target $18.33

Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 620 8655
Website: dwtx.com
Address:
44 Milton Avenue, Alpharetta, United States
jamersonmoody
jamersonmoody Oct. 26 at 5:14 AM
$DWTX see you at $5
0 · Reply
Drainomight
Drainomight Oct. 24 at 7:38 PM
$DWTX loaded up
0 · Reply
HeyHoser
HeyHoser Oct. 24 at 1:05 PM
$DWTX $5.3 support, adds down here. $4's are welcome
1 · Reply
The1Albatross
The1Albatross Oct. 21 at 3:12 PM
$DWTX Dozens of limits - few stinkies if it gets cheeky Big play to finish/start the year
2 · Reply
Arcides
Arcides Oct. 14 at 12:58 PM
$DWTX from 11.08 on sep 29 premarket high to close the gap at 5.80, complete piece of shit.
1 · Reply
tboykeyhoang
tboykeyhoang Oct. 13 at 6:21 PM
$DWTX Another spike?
0 · Reply
LadsAndGents
LadsAndGents Oct. 13 at 2:22 PM
$DWTX path to mid 7 started
0 · Reply
ZacksSCR
ZacksSCR Oct. 10 at 4:07 PM
$DWTX: Licenses SP16 for Treatment of Cancer Related Pain… https://buff.ly/8QTzxvQ
0 · Reply
HeyHoser
HeyHoser Oct. 10 at 11:56 AM
$DWTX start slow reloading again....
0 · Reply
TTXB
TTXB Oct. 10 at 12:52 AM
$DWTX The company's market value is seriously underestimated.
0 · Reply
Latest News on DWTX
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Oct 14, 2025, 8:45 AM EDT - 11 days ago

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

Oct 7, 2025, 8:45 AM EDT - 18 days ago

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

Dogwood Therapeutics, Inc. - Special Call

Sep 29, 2025, 12:17 PM EDT - 26 days ago

Dogwood Therapeutics, Inc. - Special Call

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Sep 29, 2025, 7:15 AM EDT - 26 days ago

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:15 AM EDT - 7 weeks ago

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 9:00 AM EDT - 2 months ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Aug 7, 2025, 1:08 PM EDT - 2 months ago

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Aug 6, 2025, 9:15 AM EDT - 2 months ago

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Jun 3, 2025, 9:15 AM EDT - 5 months ago

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

May 8, 2025, 9:00 AM EDT - 6 months ago

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

May 1, 2025, 8:30 AM EDT - 6 months ago

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 11, 2025, 9:15 AM EDT - 7 months ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Apr 3, 2025, 9:00 AM EDT - 7 months ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 31, 2025, 3:45 PM EDT - 7 months ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 18, 2025, 8:45 AM EDT - 7 months ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Mar 13, 2025, 9:00 AM EDT - 8 months ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Oct 7, 2024, 7:05 AM EDT - 1 year ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Aug 1, 2024, 9:41 AM EDT - 1 year ago

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

Jul 23, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 22, 2024, 1:30 PM EDT - 1 year ago

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 19, 2024, 8:53 PM EDT - 1 year ago

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17, 2024, 4:10 PM EDT - 1 year ago

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript

May 11, 2024, 11:44 PM EDT - 1 year ago

Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:45 AM EDT - 1 year ago

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

May 2, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Mar 26, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 9:15 AM EST - 1 year ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Feb 28, 2024, 9:15 AM EST - 1 year ago

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 22, 2024, 9:00 AM EST - 1 year ago

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Jan 2, 2024, 7:05 AM EST - 1 year ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 11:21 AM EST - 2 years ago

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 6, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Oct 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 18, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Sep 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 14, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 10:05 AM EDT - 2 years ago

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Aug 9, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Jul 17, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 25, 2023, 4:05 PM EDT - 2 years ago

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

May 15, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

Virios Therapeutics Announces First Quarter 2023 Financial Results

May 11, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces First Quarter 2023 Financial Results

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

May 4, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

Apr 24, 2023, 4:15 PM EDT - 2 years ago

Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 14, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

Mar 7, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023

jamersonmoody
jamersonmoody Oct. 26 at 5:14 AM
$DWTX see you at $5
0 · Reply
Drainomight
Drainomight Oct. 24 at 7:38 PM
$DWTX loaded up
0 · Reply
HeyHoser
HeyHoser Oct. 24 at 1:05 PM
$DWTX $5.3 support, adds down here. $4's are welcome
1 · Reply
The1Albatross
The1Albatross Oct. 21 at 3:12 PM
$DWTX Dozens of limits - few stinkies if it gets cheeky Big play to finish/start the year
2 · Reply
Arcides
Arcides Oct. 14 at 12:58 PM
$DWTX from 11.08 on sep 29 premarket high to close the gap at 5.80, complete piece of shit.
1 · Reply
tboykeyhoang
tboykeyhoang Oct. 13 at 6:21 PM
$DWTX Another spike?
0 · Reply
LadsAndGents
LadsAndGents Oct. 13 at 2:22 PM
$DWTX path to mid 7 started
0 · Reply
ZacksSCR
ZacksSCR Oct. 10 at 4:07 PM
$DWTX: Licenses SP16 for Treatment of Cancer Related Pain… https://buff.ly/8QTzxvQ
0 · Reply
HeyHoser
HeyHoser Oct. 10 at 11:56 AM
$DWTX start slow reloading again....
0 · Reply
TTXB
TTXB Oct. 10 at 12:52 AM
$DWTX The company's market value is seriously underestimated.
0 · Reply
Drugtrade
Drugtrade Oct. 9 at 5:03 PM
$DWTX see you at 4
0 · Reply
MrDDSteele
MrDDSteele Oct. 9 at 4:56 PM
$DWTX new coming , they are selling this off.
0 · Reply
somaopp
somaopp Oct. 9 at 3:52 PM
$DWTX why is this tanking??
0 · Reply
MrDDSteele
MrDDSteele Oct. 8 at 5:53 PM
$DWTX theu have any news coming up.
0 · Reply
PremarketAnalysis
PremarketAnalysis Oct. 7 at 1:51 PM
$DWTX showing sustained bid support with buy surge detected near 6.80.. structure tightening as buyers step in.. watching for clean push over 7.00 to confirm trend extension Momentum Feed: https://premarketanalysis.com/#momentum=DWTX
0 · Reply
DARKP00L
DARKP00L Oct. 7 at 1:03 PM
$DWTX 08:49 on Oct. 07 2025 Dogwood Therapeutics Announces Its CMO Will Present An Overview Of The Halneuron Pain Management Research Program At 19th Annual Pain Therapeutics Summit On October 14, 2025 #tradeideas
0 · Reply
DARKP00L
DARKP00L Oct. 7 at 12:54 PM
$DWTX 08:49 on Oct. 07 2025 Dogwood Therapeutics Announces Its CMO Will Present An Overview Of The Halneuron Pain Management Research Program At 19th Annual Pain Therapeutics Summit On October 14, 2025 #tradeideas
0 · Reply
Cyberwolf2077
Cyberwolf2077 Oct. 7 at 12:46 PM
$DWTX Tbh outlook looks good and their research is needed
0 · Reply
basti22
basti22 Oct. 6 at 6:47 PM
$DWTX
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 3 at 2:38 PM
$DWTX Current Stock Price: $6.90 No options data available.
0 · Reply
Drugtrade
Drugtrade Oct. 2 at 7:27 PM
$DWTX if ur in this forna quick trade then use a stop loss for chrisakes
0 · Reply
ByBi
ByBi Oct. 2 at 2:21 PM
$DWTX You guys realize that all the outstanding shares are owned by the same people, right ? Right ??
1 · Reply